TBB BUREAU BHUBANESWAR, JANUARY 24, 2022 In view of the significant rise observed in eye disorders detected, ophthalmologists suggest that the population of glaucoma patients in India is expected to double by 2040. In India, nearly 12 million are affected by glaucoma with an estimated 40-50 percent eye disorder cases going undetected. Glaucoma is one of the leading causes of ...

TBB BUREAU BHUBANESWAR, JANUARY 20, 2022 With a focus on innovating products that improve patients’ lives, Novo Nordisk India launched the world’s first and only “peptide in a pill”, oral semaglutide, a gamechanger in diabetes management. Semaglutide, a GLP-1 receptor analogue (GLP-1 RA) – one of the drug classes to treat diabetes, till now was available only in the form ...

TBB BUREAU BHUBANESWAR, JANUARY 16, 2022 On the occasion of the Foundation Day of L V Prasad Eye Institute (LVPEI) Mithu Tulsi Chanrai Campus Bhubaneswar on Sunday, a new facility, “NTPC Operating Room Complex,” was inaugurated. NTPC Executive Director (HR) MSD Bhattamishra inaugurated the NTPC Operating Room Complex from New Delhi via virtual connect. Speaking during the event, Bhattamishra said ...

TBB BUREAU BHUBANESWAR, JANUARY 16, 2022 Three new facilities — NTPC Operating Room Complex, courtesy NTPC Ltd; and Digital Library and Special Needs Vision Clinic for persons and children with vision loss and special needs, courtesy Columbus Global Services India Pvt Ltd. — were inaugurated at LV Prasad Eye Institute (LVPEI) Mithu Tulsi Chanrai Campus here today on the occasion ...

TBB BUREAU BHUBANESWAR, JANUARY 16, 2022 Mom Hand, a leading start-up, today launched its first of kind multivitamin ‘Chennapoda’ for immunity conscious customers. This famous sweetmeat of Odisha will help in increasing one’s immunity which is very important during this challenging time, claimed the company. A team of experts has developed this delicious and healthy ‘Chennapoda’ after extensive research and ...

TBB BUREAU BHUBANESWAR, JANUARY 14, 2022 It is unlikely that anytime soon, the world will enter into pre-Covid era. Instead, it is likely that we will have to co-exist with Delta and Omicron variants of the Covid-19 in time to come as both these variants will continue to co-circulate. This was stated by virologists and health experts at Neuberg Diagnostics’ ...

TBB BUREAU HYDERABAD, JANUARY 12, 2022 Covaxin’s booster dose is able to neutralise the vaccine evading Omicron variant of Covid-19, according to a study conducted at US’ Emory University, Bharat Biotech announced on Wednesday. The new study demonstrated “sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin (BBV152), ...

TBB BUREAU HYDERABAD, JANUARY 8, 2022 Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced the results from the highly anticipated trial studying the immunogenicity and safety of the COVAXIN (BBV152) a whole-virion inactivated COVID-19 vaccine as a booster dose. This analysis re-emphasizes Bharat Biotech’s continued efforts to stay ahead of COVID-19, ...

TBB BUREAU BHUBANESWAR, JANUARY 7, 2022 TP Central Odisha Distribution Limited (TPCODL), a joint venture between Tata Power and the Government of Odisha, in line with the principle of empowering the community in its area of operations, launched its second Mobile Heath Dispensary for the benefit of rural communities of Cuttack district under its CSR Program. The dispensary was inaugurated ...

TBB BUREAU BHUBANESWAR, JANUARY 6, 2021 Since the start of the pandemic, Livinguard, the Swiss-based international leader in sustainable & self-disinfecting hygiene technology, has consistently showcased >99% efficacy against SARS-CoV-2 and its variants, with no recovery of viable viruses, and Omicron will be no different. It has been proven effective against the human coronavirus 229E, the original wild variant of ...